WSTHealthcare · Medical Instruments & SuppliesThe 16 Wall Street analysts covering West Pharmaceutical Services, Inc. hold a median 12-month price target of $480 — +17.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores West Pharmaceutical Services, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (98): Analysts have, on balance, been raising their forecasts.
Accruals (41): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on WST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +17.5% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Oct 2026 | Barclays | Maintains | Overweight | $440 → $500 |
| 30 Oct 2026 | Citigroup | Maintains | Buy | $412 → $494 |
| 30 Oct 2026 | Evercore ISI Group | Maintains | Outperform | $440 → $480 |
| 30 Oct 2026 | TD Cowen | Maintains | Buy | $420 → $500 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $410 → $420 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | — |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $400 → $440 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | — |
| 22 Sept 2026 | Morgan Stanley | Upgrade | Overweight | $365 → $400 |
| 22 Sept 2026 | Morgan Stanley | Upgrade | Overweight | — |
| 9 Sept 2026 | UBS | Maintains | Buy | $340 → $415 |
| 9 Sept 2026 | UBS | Maintains | Buy | — |
| 3 Aug 2026 | Citigroup | Maintains | Buy | $400 → $412 |
| 3 Aug 2026 | Citigroup | Maintains | Buy | — |
| 27 July 2026 | Evercore ISI Group | Maintains | Outperform | $410 → $425 |
| 27 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 13 July 2026 | BNP Paribas | Initiates | Outperform | $447 |
| 13 July 2026 | BNP Paribas | Initiates | Outperform | — |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $325 → $365 |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
WST appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, West Pharmaceutical Services, Inc. returned +42.9% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 16% of US stocks
Cheaper than 15% of US stocks
Cheaper than 9% of US stocks
Cheaper than 8% of US stocks
Higher than 49% of US stocks
Higher than 76% of US stocks
Higher than 46% of US stocks
Higher than 84% of US stocks
Higher than 81% of US stocks
Higher than 82% of US stocks
Higher than 95% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
West Pharmaceutical Services, Inc. has a market value of $28.5B and an enterprise value of $28.3B.
Revenue in the twelve months to 30 June 2026: $3.3B. The latest quarter grew 8.7% year on year.
Net income over the same four quarters: $564.9M, a 17.0% net margin.
Diluted earnings per share, trailing twelve months: $7.81.
Free cash flow in the twelve months to 30 June 2026: $436.9M, after $225.3M of capital spending.
West Pharmaceutical Services, Inc. spent $457.1M on share buybacks and $62.4M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 45.9×; forward P/E: 39.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.22%, paying out 10% of earnings.
West Pharmaceutical Services, Inc. employs 10,000 people — $333K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own West Pharmaceutical Services, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
West Pharmaceutical Services announced that it will present at the Jefferies Global Healthcare Conference on November 18, 2026, at 8:00 a.m. GMT in London.
Why it matters — The scheduled presentation is an upcoming opportunity for investors to hear from West at a healthcare conference.
West Pharmaceutical Services reported third-quarter results that exceeded its expectations, supported by continued demand for high-value components used in GLP-1 therapies and biologics. Following the quarter, it raised its full-year revenue and adjusted earnings outlook.
Why it matters — The results and outlook revision highlight demand for WST’s high-value components and the company’s updated expectations for the year.
Seeking Alpha published a transcript of West Pharmaceutical Services, Inc.’s Q3 2026 earnings call. The provided excerpt contains no further details about the discussion.
Why it matters — The transcript may provide WST watchers with management’s commentary on the company’s third-quarter results and outlook, but no specific information is included in the excerpt.
West Pharmaceutical Services reported higher third-quarter earnings and revenue, supported by high-value products and margin expansion, and raised its 2026 sales and earnings outlook.
Why it matters — The results and higher outlook provide WST watchers with an update on performance and management’s expectations for 2026.
Zacks Investment Research says West Pharmaceutical’s Q3 revenue and EPS provide a view of its performance for the quarter ended September 2026, while highlighting the comparison of key metrics with Wall Street estimates and year-ago figures.
Why it matters — These comparisons provide additional context for assessing WST’s quarterly performance.
The 16 Wall Street analysts covering West Pharmaceutical Services, Inc. have a median 12-month price target of $480, with estimates ranging from $340 to $500. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering West Pharmaceutical Services, Inc., 15 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks West Pharmaceutical Services, Inc. 96 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, West Pharmaceutical Services, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (98 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +17.5% from the last close, and Ticker Nerd's factor model ranks West Pharmaceutical Services, Inc. 96 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering West Pharmaceutical Services, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $340 to $500 over the next 12 months.
West Pharmaceutical Services, Inc. returned +42.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
West Pharmaceutical Services Inc. is a healthcare products manufacturer focused on the design, development, and production of containment and delivery systems for injectable drugs and other healthcare products.
The most recent item we track (PRNewsWire, 4 Nov 2026): "West to Participate in Upcoming Investor Conference". West Pharmaceutical Services announced that it will present at the Jefferies Global Healthcare Conference on November 18, 2026, at 8:00 a.m. GMT in London.
West Pharmaceutical Services Inc. is a healthcare products manufacturer focused on the design, development, and production of containment and delivery systems for injectable drugs and other healthcare products. The company supplies critical components such as stoppers, seals, syringe and cartridge parts, reconstitution and transfer systems, safety and administration devices, and advanced injection solutions that support the packaging and delivery of pharmaceuticals and biologics. It also provides contract manufacturing and analytical lab services through its proprietary and contract-manufactured product segments. West Pharmaceutical Services Inc. serves a broad customer base that includes pharmaceutical, biotechnology, generic-drug, medical device, and consumer healthcare companies. Headquartered in Exton, Pennsylvania, the company plays an important role in the healthcare supply chain by helping enable safe, reliable, and efficient delivery of injectable therapies worldwide.
CEO Mr. Michel Lagarde · 10,000 employees · United States · https://www.westpharma.com
